Mural Health is redefining patient and site support in clinical research by putting people first—employees, patients, and sites—and using structured, transparent feedback loops to continuously improve. By combining empathy and data to improve the clinical trial experience for patients, sites, and sponsors alike, Mural Health is helping all stakeholders build trust and make smarter
For Takeda, evolving the way they work with clinical research sites wasn’t optional — it was essential. The company recognized that relying too heavily on outsourcing was damaging their relationship with sites, slowing progress, and limiting their ability to deliver treatments to patients faster. The answer was clear: take greater accountability for their own
In clinical research, simplification isn’t a luxury. It’s a necessity. At GSK, that guiding principle is redefining their approach to study start-up, site engagement, and operational systems. Through bold investments in technology, including automation, and a clear focus on reducing site burden, GSK is working to turn administrative obstacles into opportunities for connection and
In clinical research, strong relationships between CROs and clinical sites are built on more than just well-designed protocols. They require mutual understanding, proactive communication, and systems that reinforce trust. That’s where the PPD™ clinical research business of Thermo Fisher Scientific’s Strategic Site Collaborations (SSC) team steps in. As part of our Collaborate Forward
In clinical research, operational improvements often begin with tools, templates, and timelines. However, at Fortrea, the driving force behind smoother study start-up is something more fundamental: relationships. Through a deliberate shift in culture, structure, and leadership mindset, Fortrea is creating more trusted, responsive connections with investigative sites. The result is not only improved
Clinical research thrives on collaboration—but too often, inefficiencies, siloed systems, and reactive processes slow things down. That’s why Collaborate Forward exists: to spotlight real-world examples of how clinical research stakeholders—sites, CROs, sponsors, and tech partners—can work better together. Through a series of conversations across the industry, we’re identifying key pillars of effective collaboration:
As clinical research continues to grow in complexity, the gap between technology providers and clinical sites has often widened. Too frequently, solutions are built for sites without truly being built with them—leading to frustration, poor adoption, and slower progress. Through the Collaborate Forward initiative, we’ve been exploring how collaboration—across people, process, communication, and
The clinical trial landscape is increasingly shaped by complexity, particularly in oncology. Precision medicine protocols, narrow eligibility criteria, and evolving therapeutic approaches make strong site partnerships essential. For TD2, a specialty contract research organization (CRO) focused on oncology, that challenge is met not through scale, but through agility, intentional listening, and strategic collaboration.
Collaboration has always been central to clinical research—but true partnership requires more than good intentions. It demands a shift in mindset, a commitment to mutual respect, and the humility to listen and adapt. That’s exactly what Sanofi is doing. As part of our Collaborate Forward initiative, we’re speaking with clinical research stakeholders across
